Global Thyroid Eye Disease (TED) Treatment Market Research Report 2023-2029: Strategic Recommendations Include Minimally Invasive Surgical Techniques and Expansion into Iron Deficient Regi...
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering. During the forecast period, 2024-2029, the Global Thyroid Eye Disease Treatment market is expected to grow at a CAGR of 13.24%. The Global Thyroid Eye Disease Treatment Market is expected to generate USD 8.24 Billion by the end of 2029, up from USD 3.46 Billion in 2022. . The research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast. The research also analyzes growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market's evolution. . The market for treatments of thyroid eye disease (TED) is witnessing substantial expansion as a result of the increasing prevalence of this ailment. Gr
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024Business Wire
- Foghorn Therapeutics appoints Kristian Humer as chief financial officer [Seeking Alpha]Seeking Alpha
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the FirmPR Newswire
VRDN
Earnings
- 11/13/23 - Beat
VRDN
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- VRDN's page on the SEC website